scholarly journals Breast cancer treatment in clinical practice compared to best evidence and practice guidelines

2004 ◽  
Vol 90 (1) ◽  
pp. 26-30 ◽  
Author(s):  
B S Bloom ◽  
N de Pouvourville ◽  
S Chhatre ◽  
R Jayadevappa ◽  
D Weinberg
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cancer Treatment ◽  
Practice Guidelines ◽  
Breast Cancer Treatment

scholarly journals Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment

2017 ◽  
Vol 67 (3) ◽  
pp. 194-232 ◽  
Author(s):  
Heather Greenlee ◽  
Melissa J. DuPont-Reyes ◽  
Lynda G. Balneaves ◽  
Linda E. Carlson ◽  
Misha R. Cohen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cancer Treatment ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Breast Cancer Treatment ◽  
Evidence Based ◽  
Integrative Therapies

scholarly journals Change in clinical practice after publication of guidelines on breast cancer treatment

2009 ◽  
Vol 21 (5) ◽  
pp. 372-378 ◽  
Author(s):  
H. Fukuda ◽  
Y. Imanaka ◽  
T. Ishizaki ◽  
K. Okuma ◽  
T. Shirai
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cancer Treatment ◽  
Breast Cancer Treatment

scholarly journals Ribociclib in 1st line HR+ breast cancer treatment

2018 ◽  
Vol 20 (2) ◽  
pp. 38-41 ◽  
Author(s):  
L G Zhukova ◽  
I P Ganshina ◽  
O O Gordeeva ◽  
E V Lubennikova
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Great Demand ◽  
New Approaches ◽  
Phase Iiib ◽  
Clinical Cases

Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.

Sign in / Sign up

Export Citation Format

Share Document